menu
    • menu
    [{"orgOrder":0,"company":"Hinge Bio","sponsor":"Ridgeback Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"HB2198","moa":"CD19\/20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hinge Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ Ridgeback Capital","highestDevelopmentStatusID":"5","companyTruncated":"Hinge Bio \/ Ridgeback Capital"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Hinge Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Hinge Bio \/ Undisclosed"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"HB2198","moa":"CD19\/20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hinge Bio","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ KYORIN PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"5","companyTruncated":"Hinge Bio \/ KYORIN PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"HB2198","moa":"CD19\/20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hinge Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Hinge Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Hinge Bio

    Menu

    Hinge Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HB2198

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hinge Bio's HB2198 FDA Cleared for Lupus Erythematosus and Nephritis

                            Details : HB2198, an unconjugated antibody targeting CD19/20, shows promise in treating Systemic Lupus Erythematosus (SLE).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 13, 2025

                            Lead Product(s) : HB2198

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HB2198

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : KYORIN PHARMACEUTICAL CO LTD

                            Deal Size : $105.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical

                            Details : The agreement aims for the development of Hinge’s multispecific antibody-based therapeutic HB2198 in Japan for Systemic Lupus Erythematosus.

                            Product Name : HB2198

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $10.0 million

                            September 30, 2025

                            Lead Product(s) : HB2198

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : KYORIN PHARMACEUTICAL CO LTD

                            Deal Size : $105.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HB2198

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Ridgeback Capital

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Hinge Bio Secures $30M Series A’ for GEM-DIMER Platform Therapies

                            Details : The proceeds will support the Company in advancing its lead product candidate, HB2198, into a clinical trial in patients living with Systemic Lupus Erythematosus.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 15, 2025

                            Lead Product(s) : HB2198

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Ridgeback Capital

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hinge Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development

                            Details : GEM-DIMER™ molecule may improve the therapeutic benefit by incorporating antibody and other protein domains that direct tumor targeting, T/NK/macrophage effector cell engagement and effector cell activation, as well as to localize activity of tumor mic...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth